Osteopore (ASX:OSX) has announced that US-based distributor Bioplate has secured a non-exclusive agreement with MellingMedical to promote and sell its products within healthcare facilities owned or operated by the US government.
Osteopore specialises in the manufacture of regenerative implants that empower natural tissue regeneration.
Under the terms of the Agreement, MellingMedical will market and sell Osteopore’s FDA-cleared products to healthcare facilities owned or operated by the US government, both domestically and internationally.
Osteopore said the initial focus will be supplying products to Veteran’s Affairs (VA) and Department of Defense facilities that have neuro and trauma surgery capabilities.
Executive chairman Mark Leong said, “This is an important and progressive milestone in the execution of our strategy of extending our presence in a key market like the USA. Working closely with MellingMedical, we now have inroads to their wide and considerable access to VA-related medical facilities and clinics throughout USA and helps extend the footprint of our products. We are all enthused with this latest development and credit the team for imprinting Osteopore as a viable solution in the USA cranial market.”
Bioplate CEO Thomas Hopson said, “We are excited about this agreement because it allows the VA, military hospitals, and other government facilities an opportunity to have access this novel technology. The Osteopore products address a clinical need that has not been solved with traditional cranial closure products.”
Founder and CEO of MellingMedical, Chris Melling, added, “We are amazed at the efficacy of Osteopore’s solutions and their ability to enhance and accelerate the body’s natural regenerative processes. Their technology’s potential to improve the quality of life for patients recovering from injury or even congenital skeletal defects is a game changer.”